People: ViroPharma Inc (VPHM.OQ)
VPHM.OQ on NASDAQ Stock Exchange Global Select Market
32.00USD
1 Aug 2013
32.00USD
1 Aug 2013
Price Change (% chg)
$-2.32 (-6.76%)
$-2.32 (-6.76%)
Prev Close
$34.32
$34.32
Open
$32.70
$32.70
Day's High
$33.16
$33.16
Day's Low
$31.40
$31.40
Volume
895,421
895,421
Avg. Vol
232,585
232,585
52-wk High
$35.18
$35.18
52-wk Low
$19.59
$19.59
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Vincent Milano |
49 | 2008 | Chairman of the Board, President, Chief Executive Officer |
Charles Rowland |
54 | 2012 | Chief Financial Officer, Vice President |
Daniel Soland |
54 | 2008 | Vice President, Chief Operating Officer |
John Kirby |
41 | 2012 | Chief Accounting Officer, Vice President |
Colin Broom |
57 | 2004 | Vice President, Chief Scientific Officer |
Robert Fletcher |
50 | 2011 | Vice President - Business Development and Project Management |
John Wolf |
43 | 2008 | Vice President, General Counsel, Secretary |
Thomas Doyle |
52 | 2008 | Vice President - Strategic Initiatives |
Robert Pietrusko |
64 | 2007 | Vice President - Global Regulatory Affairs and Quality |
Howard Pien |
54 | 2008 | Lead Independent Director |
Paul Brooke |
68 | 2001 | Independent Director |
William Claypool |
61 | 2003 | Independent Director |
Michael Dougherty |
53 | 2004 | Independent Director |
Robert Glaser |
58 | 1997 | Independent Director |
John Leone |
65 | 2006 | Independent Director |
Julie McHugh |
48 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Vincent Milano |
Mr. Vincent J. Milano is Chairman of the Board, President, Chief Executive Officer of VioPharma Inc. Mr. Milano joined the company in 1996, and has served as President and Chief Executive Officer since March 31, 2008. He became Chairman of the Board of Directors in December 2008. He served as Chief Operating Officer from January 2006 to March 2008 and as Vice President, Chief Financial Officer of ViroPharma from November 1997 to March 2008. Mr. Milano has previously served as Vice President, Finance & Administration, as Treasurer, and as Executive Director, Finance & Administration. Prior to joining ViroPharma, Mr. Milano was with KPMG LLP, independent certified public accountants, where he was a Senior Manager. Mr. Milano has served on the board of directors of Vanda Pharmaceuticals Inc. since April 2010 and served on the board of directors of Verticalnet, Inc. from August 2003 until the company was acquired by BravoSolution S.p.A. in January 2008. Mr. Milano received his Bachelor of Science degree in Accounting from Rider College. |
Charles Rowland |
Mr. Charles A. Rowland is Chief Financial Officer, Vice President of ViroPharma Inc. Prior to joining ViroPharma, Mr. Rowland served as Executive Vice President, Chief Financial Officer of Endo Pharmaceuticals from December 2006 to September 2008. Prior thereto, Mr. Rowland was Senior Vice President and CFO of Biovail Pharmaceuticals, Inc. from 2004 to 2006. From 2001 to 2004, he was Chief Operating and Financial Officer for Breakaway Technologies, a management consulting company. His pharmaceutical industry career includes positions of increasing scope and responsibility at Pharmacia Corp., where he had global responsibility for Finance and Information Technology for the Pharmaceutical Business and financial responsibility for the Global Supply organization as Vice President, Finance Global Supply and VP Finance & IT-Global Pharma Ops; Novartis Pharmaceuticals Corp., where he was Vice President, Planning and Decision Support, and Bristol-Myers Squibb, where he served as Director of Finance. Mr. Rowland received his Bachelor of Science degree in Accounting from St. Joseph’s University and a MBA from Rutgers University. |
Daniel Soland |
Mr. Daniel B. Soland is Vice President, Chief Operating Officer of ViroPharma Inc. He joined ViroPharma in November 2006 as Vice President, Chief Commercial Officer and has served as Chief Operating Officer since March 2008.From February 2005 until June 2006, Mr. Soland served as President of Chiron Vaccines. From March 2003 until February 2005, Mr. Soland was President and Chief Executive Officer at Epigenesis Pharmaceuticals, a privately held biopharmaceutical company. Prior to that, Mr. Soland spent nine years with GlaxoSmithKline as the Vice President and Director of Worldwide Marketing Operations, and five years as GSK's Vice President and Director of the U.S. Vaccines Business Unit. Mr. Soland holds a Bachelor of Science degree in Pharmacy from the University of Iowa, in Iowa City, IA. |
John Kirby |
Mr. John J. Kirby is Chief Accounting Officer, Vice President of ViroPharma Incorporated, since August 20, 2012. From 2010 to 2012 Mr. Kirby held positions of increasing responsibility with AstraZeneca Pharmaceuticals, most recently as the Regional Audit Director—Americas. Prior to that, Mr. Kirby worked for KPMG LLP for fourteen years where he held positions of increasing responsibility, most recently as Senior Manager. Mr. Kirby received his bachelor of science degree in accounting from Villanova University and is a certified public accountant. |
Colin Broom |
Dr. Colin Broom is Vice President, Chief Scientific Officer of ViroPharma Inc., since May 2004. From 2000 until 2003, Dr. Broom served as Vice President of Clinical Development and Medical Affairs, Europe, for Amgen. From 1998 to 1999, Dr. Broom served as Senior Vice President of Global Clinical Development for Hoechst Marion Roussel, now Sanofi-Aventis. From 1984 until 1998, Dr. Broom was with Glaxo and then SmithKline Beecham, where he held positions of increasing seniority in clinical pharmacology in Europe before moving to the U.S. to head global oncology and subsequently becoming Vice President of CNS/GI. Dr. Broom holds a Bachelor of Science degree in Pharmacology from University College London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School. Dr. Broom is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians. Dr. Broom has been a director of NPS Pharmaceuticals since July 2009. |
Robert Fletcher |
Mr. Robert C. Fletcher is Vice President - Business Development and Project Management of ViroPharma Inc. Mr. Fletcher joined ViroPharma in 2001 as a project leader, and has since held roles of increasing responsibility during his tenure in the areas of business development and project management. Prior to joining ViroPharma, Mr. Fletcher held multiple roles of escalating responsibility at SmithKline Beecham Pharmaceuticals/GlaxoSmithKline, Becton-Dickinson and Company, Zynaxis Inc./Intracell Corporation, and Centocor Corporation. He holds both a master of science degree and a bachelor of arts degree in biology from Wake Forest University. |
John Wolf |
Mr. John Peter Wolf is Vice President, General Counsel, Secretary of ViroPharma Inc., since January 1, 2008. Mr. Wolf previously served as Associate General Counsel of ViroPharma since 2004. From 1995 to 2004 Mr. Wolf was a corporate attorney at private law firms. Mr. Wolf received his J.D. from the George Washington University National Law Center and his Bachelor of Arts from the University of Delaware. |
Thomas Doyle |
Mr. Thomas F. Doyle is Vice President - Strategic Initiatives of ViroPharma Inc., since January 1, 2008. Mr. Doyle previously served as Vice President, General Counsel of ViroPharma from November 1997 to January 2008, as Secretary from February 1997 to January 2008 and as Executive Director, Counsel since joining ViroPharma in November 1996 to February 1997. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his Bachelor of Science degree in Accounting from Mt. St. Mary's College. |
Robert Pietrusko |
Dr. Robert G. Pietrusko is Vice President - Global Regulatory Affairs and Quality of ViroPharma Inc., since May 1, 2007. Prior to joining ViroPharma, Dr. Pietrusko served as Senior Vice President of Worldwide Regulatory Affairs for Millennium Pharmaceuticals, Inc. from 2001 through May 2007. Dr. Pietrusko spent 19 years at GlaxoSmithKline, culminating in his tenure as Vice President and Director, Anti-infective and Antiviral Therapeutic Areas, U.S. Regulatory Affairs Dr. Pietrusko holds a Bachelor of Science degree in Biology and a Bachelors of Pharmacy degree from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. |
Howard Pien |
Mr. Howard H. Pien is Lead Independent Director of ViroPharma Incorporated. Mr. Pien has served as one of the directors since May 2006 and has served as the lead independent director since December 2008. Mr. Pien is the former chief executive officer and President of Medarex, a biotechnology company. He served in this capacity from June 2007 until Medarex’s merger with Bristol-Myers Squibb in September 2009. Mr. Pien served as the President and Chief Executive Officer and a Director of Chiron Corporation from April 2003 until Chiron’s merger with Novartis in April 2006. Mr. Pien was elected Chairman of the Board of Directors of Chiron in May 2004. He joined Chiron from GlaxoSmithKline, where he had responsibility as President, Pharmaceuticals International from December 2000 to March 2003. Mr. Pien previously held key positions in SmithKline Beecham’s pharmaceuticals business in the United States, the United Kingdom, and North Asia, North America, culminating in his tenure as President, Worldwide Pharmaceuticals. Prior to joining SmithKline Beecham, he worked six years for Abbott Laboratories and five years for Merck & Co., in positions of sales, marketing research licensing and product management. Mr. Pien previously served as a director of ViroPharma Incorporated from 1998 to 2003, and currently serves as a director of Vanda Pharmaceuticals, Inc. and ImmunoGen, Inc., both public companies engaged in drug development. He also serves as a director of Ikaria, a private company engaged in life sciences, as well as an advisor to Warburg Pincus, a private equity firm. Mr. Pien has also previously served on the Boards of Oakland Children’s Hospital, Chiron and Medarex. Mr. Pien holds a B.S. degree from Massachusetts Institute of Technology and an M.B.A. from Carnegie-Mellon University. |
Paul Brooke |
Mr. Paul A. Brooke is Independent Director of ViroPharma Incorporated since February 12, 2001. Mr. Brooke is Managing Director and founding partner of venBio, an investment firm. He was a founder, chairman and chief executive officer of Ithaka Acquisition Corp, a firm subsequently merged into Alsius Corporation where he was Chairman. Alsius was subsequently sold to Zoll Medical Corporation. Since 1993 Mr. Brooke has been a managing member of PMSV Holdings LLC. He also was a venture partner of MPM Capital through 2005 and an Advisory Director of Morgan Stanley & Co. from 2000 to 2009. He was a managing director at Tiger Management LLC from April 1999 to May 2000. Mr. Brooke was a managing director at Morgan Stanley and was global head of healthcare research and strategy from March 1983 to April 1999. Mr. Brooke also is a director of WebMD.com, Incyte Corporation, Cheyne Capital International Limited and Manning and Napier Advisors. Mr. Brooke has also served as a director of MPM Bioequities Fund and Alsius. |
William Claypool |
Dr. William D. Claypool, M.D., is Independent Director of ViroPharma Incorporated since December 2003. Dr. Claypool is currently a Senior Partner at Pennmark Associates, LLC, a pharmaceutical development consulting firm. He was previously President of Phoenix Data Systems, a wholly owned subsidiary of Bio-Imaging Technologies, Inc., now BioClinica, Inc. (BIOC). Prior to this, from June 2001 until March 2008, he was Chief Executive Officer and Chairman of the Board at Phoenix Data Systems, Inc. From January 2001 until June 2001 he served as President and chief executive officer of The GI Company. From 1991 to 2001 Dr. Claypool held a number of management positions with SmithKline Beecham Pharmaceuticals, serving from November 1998 to December 2000 as Senior Vice-President and Director of Worldwide Clinical Research and Medical Affairs. Dr. Claypool is also currently on the Board of Directors for Cipher Pharmaceuticals. Dr. Claypool was a member of the Board of Directors and served on the Audit Committee of 3 Dimensional Pharmaceuticals from January 2002 to April 2003 when it was acquired by Johnson and Johnson. Dr. Claypool was a member of the Board of Directors of Morphotek from March 2005 until April 2007 when it was acquired by Eisai Corporation. While at Morphotek, he served on the Audit Committee. Dr. Claypool received his medical degree from the University of Connecticut School of Medicine. |
Michael Dougherty |
Mr. Michael R. Dougherty is Independent Director of ViroPharma Incorporated since January 2004. Mr. Dougherty was the President and Chief Executive Officer of Adolor Corp. and a member of the Board of Directors of Adolor from December 2006 until December 2011. Mr. Dougherty joined Adolor as Senior Vice President of Commercial Operations in November 2002, and until his appointment as President and Chief Executive Officer in December 2006, served in a number of capacities, including Chief Operating Officer and Chief Financial Officer. From November 2000 to November 2002, Mr. Dougherty was President and Chief Operating Officer of Genomics Collaborative, Inc., a privately held functional genomics company. Previously, Mr. Dougherty served in a variety of senior positions at Genaera Corporation, formerly Magainin Pharmaceuticals Inc., a publicly-traded biotechnology company, including as President and Chief Executive Officer and at Centocor, Inc., a publicly-traded biotechnology company, including as Senior Vice President and Chief Financial Officer. Mr. Dougherty received a B.S. from Villanova University. Mr. Dougherty had served on the board of directors of Adolor and previously served on the board of directors of Genaera. |
Robert Glaser |
Mr. Robert J. Glaser is Independent Director of ViroPharma Incorporated since August 1997. Currently Mr. Glaser is a Senior Partner of Pennmark Associates, a managing consulting group to the pharmaceutical industry. From 2004 to 2008, he was Chief Marketing and Sales Officer for Indegene, Inc., a medical education and e-learning company. During 2004, Mr. Glaser was Executive Vice President of Sales and Marketing of Ancillary Care Management, a healthcare management company. During 2003, Mr. Glaser was Senior Vice President of Caliber Associates. From 2001 to 2002, Mr. Glaser was a consultant to the biotechnology and pharmaceutical industries. From 1998 to 2001, Mr. Glaser was President of the McKesson HBOC Pharmaceutical Services division of McKesson HBOC. He was President and Chief Operating Officer of Ostex International from 1996 to 1997. Mr. Glaser was Senior Vice President of Marketing for Merck U.S. Human Health from 1994 to 1996, Vice President of Marketing from 1993 to 1994 and Vice President of Merck’s Vaccine Division from 1991 to 1993. |
John Leone |
Mr. John R. Leone is Independent Director of ViroPharma Incorporated, since January 19, 2006. Mr. Leone joined Paul Capital, a private equity investment firm, in 2007 with over 30 years of pharmaceutical industry experience. Prior to joining Paul Capital, he was President and Chief Executive Officer of Cambrex Corporation, a life sciences company from August 2004 to January 2006. From 2000 to 2004, Mr. Leone was at Aventis, where he served as Senior Vice President and Chief Operating Officer of U.S. Commercial Operations. In this position he had responsibility for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective. Among other initiatives, Mr. Leone helped spearhead the integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst Marion Roussel, to form Aventis. His industry experience also includes both domestic and international executive management roles with Wyeth, where he held the following positions during his tenure: General Manager Ayerst International, General Manager of commercial operations for Ayerst U.S., Group Vice President of Wyeth International Marketing and General Manager Vaccine and Pediatric Division. Mr. Leone started his healthcare career at Pfizer Laboratories, where he held various senior marketing positions in both the U.S. and International groups and was responsible for the commercial launch of numerous pharmaceutical products. Mr. Leone previously served on the Board of Directors for Forticell BioSciences, Inc., Oscient Pharmaceuticals, Inc. and Cambrex. Mr. Leone received his BS degree in Engineering from the U.S. Military Academy at West Point and his MBA from the University of Colorado. |
Julie McHugh |
Ms. Julie H. McHugh has been appointed as Independent Director of ViroPharma Inc., effective January 03, 2012. Ms. McHugh is currently the Chief Operating Officer of Endo Pharmaceuticals Holdings Inc. and has held this position since March 2010. Prior to joining Endo, Ms. McHugh was the Chief Executive Officer of Nora Therapeutics, Inc., a venture capital backed biotech start-up focused on developing novel therapies for the treatment of infertility disorders. Prior to joining Nora Therapeutics, she was Company Group Chairman for Johnson & Johnson’s Worldwide Virology Business Unit where she led a growing area of the corporation’s pharmaceutical business, including the global launches of PREZISTA® and INTELENCE® and oversight of an R&D portfolio including compounds for HIV, Hepatitis C, and Tuberculosis. Prior to her role as Company Group Chairman, Ms. McHugh was President of Centocor, Inc., a J&J subsidiary, and was responsible for the product development and commercialization of REMICADE®, a breakthrough therapeutic for Crohn’s disease, rheumatoid arthritis and several other autoimmune disorders. Ms. McHugh received a Bachelor of Science degree from Pennsylvania State University and her masters of business administration degree from St. Joseph’s University. She currently serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University, the Board of Directors for the Nathaniel Adamczyk Foundation, and was 2009 Chairman of the Board of Directors for the Pennsylvania Biotechnology Association. In addition, Ms. McHugh is a member of the board of Biotechnology Industry Organization (BIO) in addition to NEHI, both of which are trade associations. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Vincent Milano |
3,151,760 |
Charles Rowland |
1,695,450 |
Daniel Soland |
2,209,590 |
John Kirby |
-- |
Colin Broom |
1,712,790 |
Robert Fletcher |
-- |
John Wolf |
-- |
Thomas Doyle |
1,657,580 |
Robert Pietrusko |
1,708,660 |
Howard Pien |
-- |
Paul Brooke |
-- |
William Claypool |
-- |
Michael Dougherty |
-- |
Robert Glaser |
-- |
John Leone |
-- |
Julie McHugh |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Vincent Milano |
425,193 | 5,656,520 |
Charles Rowland |
35,000 | 369,700 |
Daniel Soland |
80,000 | 1,085,000 |
John Kirby |
0 | 0 |
Colin Broom |
422,116 | 6,885,600 |
Robert Fletcher |
0 | 0 |
John Wolf |
0 | 0 |
Thomas Doyle |
350,500 | 3,933,390 |
Robert Pietrusko |
0 | 0 |
Howard Pien |
0 | 0 |
Paul Brooke |
0 | 0 |
William Claypool |
0 | 0 |
Michael Dougherty |
0 | 0 |
Robert Glaser |
0 | 0 |
John Leone |
0 | 0 |
Julie McHugh |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LEONE JOHN R |
4,500 | $0.00 |
GLASER ROBERT JOY |
4,500 | $0.00 |
DOUGHERTY MICHAEL R |
4,500 | $0.00 |
BROOKE PAUL A |
4,500 | $0.00 |
CLAYPOOL WILLIAM D |
4,500 | $0.00 |
PIEN HOWARD H |
4,500 | $0.00 |
MCHUGH JULIE |
4,500 | $0.00 |
BROOKE PAUL A |
10,000 | $1.77 |
MCHUGH JULIE |
2,083 | $0.00 |
BROOM COLIN |
10,000 | $1.84 |
BROOM COLIN |
17,500 | $22.53 |
BROOM COLIN |
17,500 | $1.84 |
BROOKE PAUL A |
60,000 | $23.87 |
BROOM COLIN |
50,000 | $8.86 |
BROOM COLIN |
14,999 | $24.07 |
BROOM COLIN |
10,000 | $24.07 |
BROOM COLIN |
14,999 | $9.96 |
BROOM COLIN |
50,000 | $24.07 |
BROOM COLIN |
10,000 | $5.91 |
WOLF JOHN PETER III |
18,000 | $24.85 |
CLAYPOOL WILLIAM D |
10,000 | $24.80 |
WOLF JOHN PETER III |
18,000 | $3.14 |
DOUGHERTY MICHAEL R |
2,500 | $25.07 |
GLASER ROBERT JOY |
10,000 | $20.15 |
GLASER ROBERT JOY |
20,000 | $3.00 |

